WAYNE, Pa., Dec. 27 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced two executive management promotions,
effective January 1, 2008. Richard J. DePiano, Jr. has been promoted to
President of Escalon Medical Corp. Escalon also announced the promotion of
Mark Wallace to Chief Operating Officer.

    Mr. DePiano, Jr. joined Escalon in 2003. He most recently served as
Chief Operating Officer and General Counsel, managing the ophthalmic
diagnostic, surgical products and vascular access business and overseeing
all legal matters. Prior to serving in this role, Mr. DePiano, Jr. served
as Vice President of Corporate and Legal Affairs. Before joining Escalon,
Mr. DePiano, Jr. engaged in private practice of law for eleven years, where
he represented individual and business clients in mergers and acquisitions,
corporate and securities law matters, venture capital financings and
general business and commercial matters.

    Mr. DePiano, Jr. received a Bachelor of Science degree from Villanova
University and a Juris Doctor Degree from Widener University School of Law.
He currently serves as President and as a member of the Board of Directors
of the Delaware Valley Corporate Counsel Association ("DELVACCA"). He also
serves as Vice Chairman of the Board of Directors of the Montgomery County
Industrial Development Authority.

    Mark Wallace's career spans over 18 years in the medical device
industry. He joined Escalon in 1997, serving most recently as Escalon's
Executive Vice President with operational responsibilities for its Escalon
Digital Solutions and Trek Medical subsidiaries. He also has held the
position of Vice President-Quality, with quality and regulatory
responsibilities for all of the Escalon companies, and has also previously
served as Operations Manager at Sonomed, Inc. and Quality Manager of
Escalon Medical. Mr. Wallace had previously worked with Lunar Corp. (now GE
Healthcare) and Trek Medical. Mr. Wallace holds a Bachelor of Science in
Industrial Engineering and a Masters of Science in Manufacturing Systems
Engineering, both from the University of Wisconsin-Madison. He is also a
senior member of the American Society of Quality.

    Richard J. DePiano, Chairman and Chief Executive Officer, commented, "I
am pleased to announce these promotions as Richard and Mark have both
demonstrated their leadership capabilities and contributed greatly to our
targeted growth strategies. I'm sure they will both continue to deliver
strong leadership for our customers, employees and shareholders."

    Founded in 1987, Escalon develops markets and distributes ophthalmic
diagnostic and surgical products as well as vascular access devices. Drew
Scientific, which operates as a separate business unit, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology,
as well as veterinary hematology and blood chemistry. Escalon seeks to
utilize strategic partnerships to help finance its development programs and
is also seeking acquisitions to further diversify its product line to
achieve critical mass in sales and take better advantage of Escalon's
distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania
and manufacturing operations in Long Island, New York, New Berlin,
Wisconsin, Dallas, Texas, Waterbury, Connecticut and Barrow-in-Furness,
U.K.

    Note: This press release contains statements that are considered
forward- looking under the Private Securities Litigation Reform Act of
1995, including statements about Escalon's future prospects. They are based
on Escalon's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether Escalon is able to:


    -- implement its growth and marketing strategies, improve upon the
       operations of Escalon's business units, including the integration of
       Drew's and MRP's operations, the reorganization of the Drew business
       and the integration of any acquisitions it may undertake, if any, of
       which there can be no assurance,
    -- implement cost reductions,
    -- generate cash,
    -- identify, finance and enter into business relationships and
       acquisitions.

    Other factors include uncertainties and risks related to:
    -- new product development, commercialization, manufacturing and market
       acceptance of new products,
    -- marketing acceptance of existing products in new markets,
    -- research and development activities, including failure to demonstrate
       clinical efficacy,
    -- delays by regulatory authorities, scientific and technical advances by
       Escalon or third parties,
    -- introduction of competitive products,
    -- third party reimbursement and physician training, and
    -- general economic conditions.
    Further information about these and other relevant risks and
uncertainties may be found in Escalon's report on Form 10-K, and its other
filings with the Securities and Exchange Commission, all of which are
available from the Commission, Escalon's website, as well as other sources.

Link to this page: